Phase II Study of a 3-Week Schedule of Irinotecan Combined with Cisplatin in Previously Untreated Extensive-Stage Small-Cell Lung Cancer

Publisher： Karger

E-ISSN： 1423-0232|73|1-2|76-80

ISSN： 0030-2414

Source： Oncology, Vol.73, Iss.1-2, 2008-03, pp. : 76-80

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Study of Weekly Irinotecan plus Cisplatin in Patients with Previously Untreated Extensive-Stage Extrapulmonary Small Cell Carcinoma

By  

Oncology Research and Treatment, Vol. 34, Iss. 7, 2011-06 ,pp. : 378-381

Karger

Access to resources Recommend Favorite

A Multicenter Phase II Study of the Combination of Irinotecan and Gemcitabine in Previously Treated Patients with Small-Cell Lung Cancer

By  

Oncology, Vol. 66, Iss. 3, 2004-06 ,pp. : 192-196

Karger

Access to resources Recommend Favorite

A Phase I Trial of a 5-Day Schedule of Intravenous Topotecan and Etoposide in Previously Untreated Patients with Small-Cell Lung Cancer

By  

Oncology, Vol. 61, Iss. 1, 2001-09 ,pp. : 25-29

Karger

Access to resources Recommend Favorite

Phase II Study of Irinotecan plus S-1 Combination for Previously Untreated Advanced Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601

By  

Oncology, Vol. 81, Iss. 2, 2011-10 ,pp. : 84-90

Karger

Access to resources Recommend Favorite

A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of the UGT1A1 and CYP2A6 Polymorphisms on Clinical Activity

By  

Oncology, Vol. 82, Iss. 5, 2012-04 ,pp. : 290-297

Karger

Access to resources Recommend Favorite